[Failed to load article at https://www.euractiv.com/section/health-consumers/news/rfk-unveils-plan-to-tackle-childhood-chronic-disease-points-to-europe/]


[TITLE]KFSHRC Concludes Strategic Role at C3 Davos of Healthcare New York Summit:
[TEXT]
NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) concluded its participation as Strategic Partner and strategic partner of the C3 Davos of Healthcare™ New York Summit: Healthcare Disrupted – The Future of AI, Data & Precision Medicine, held on September 8, 2025, at the Union League Club in New York City. The event convened global healthcare leaders, innovators, and policymakers to explore how artificial intelligence, digital platforms, and precision medicine are reshaping the future of care.

In his Welcoming Remarks, Dr. Björn Zoëga, Deputy CEO of KFSHRC, said artificial intelligence must be used to support, not replace, healthcare workers. He also announced that KFSHRC treated its first patient with locally manufactured CAR-T cells, making Saudi Arabia an early adopter of this therapy. The patient, previously unresponsive to other treatments, is now cancer-free, with costs reduced by nearly 80 percent and treatment times cut from over 100 days abroad to under 40 days locally.

Dr. Zoëga highlighted KFSHRC’s leadership in robotic surgery, including world-first transplant procedures, and pointed to investment in a genomic and experimental medicine facility backed by national leadership. He also stressed that consultants must complete at least two years of international training before joining, ensuring that global expertise strengthens Saudi healthcare.

Prof. Ahmad AbuSalah, Director of the Center for Healthcare Intelligence at KFSHRC, contributed to Session #4: Smart Hospitals – How AI is Powering Operational Efficiency, Patient Safety & Clinical Decision-Making. He presented how KFSHRC is integrating artificial intelligence into hospital operations to optimize workflows, enhance safety, and support clinical decision-making in real time. Prof. AbuSalah highlighted the hospital’s progress in predictive analytics and AI-enabled monitoring, demonstrating how technology is already improving patient outcomes and operational resilience.

Prof. Jackie Yi-Ru Ying, Chief Innovation and Research Officer at KFSHRC, highlighted the hospital’s advances in clinical research and innovation, noting that in 2024 KFSHRC conducted more than half of all active clinical trials in Saudi Arabia, modernized its Biobank to support precision medicine, and expanded its CAR-T program with successful in-house treatments, including remission for patients with limited options.

She also outlined the impact of KFSHRC’s Digital Innovation Hub and Capacity Command Centre—developing over 30 AI applications, cutting hospital turnaround times, and reducing bed-waiting from 32 to 6 hours—alongside record-setting achievements in kidney transplantation, where the hospital has become a global leader in both adult and pediatric programs.

KFSHRC has been ranked first in the Middle East and North Africa and 15th globally in the list of the world’s top 250 Academic Medical Centres for the third consecutive year and recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2025 Brand Finance rankings. Additionally, it was included in the World’s Best Smart Hospitals list for 2025 by Newsweek magazine.
[Source link]: https://www.globenewswire.com/news-release/2025/09/09/3147301/0/en/KFSHRC-Concludes-Strategic-Role-at-C3-Davos-of-Healthcare-New-York-Summit.html


[TITLE]Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance:
[TEXT]
MINNEAPOLIS, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (“Celcuity”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it has entered into an amendment to its existing senior secured credit facility with an affiliate of Innovatus Capital Partners, LLC (“Innovatus”) and Oxford Finance LLC, and its affiliates (together, “Oxford”). The amendment increases the total term loan facility size to $500 million, including $350 million in committed capital and up to $150 million at the mutual discretion of Celcuity and its lenders. At the closing of the Amendment, the initial funding under the amended credit facility was in a principal amount of $30 million, bringing the total term loan outstanding to $130 million.

Highlights of the amended credit facility include:

Increased Capital Availability: Adds $170 million in new committed capital, including an additional $50 million for a total of $100 million available upon U.S. Food and Drug Administration (“FDA”) approval of gedatolisib in second-line wild-type advanced breast cancer (“ABC”) patients post-CDK4/6 inhibitor therapy, and $120 million upon achievement of certain commercial revenue milestones. An additional up to $150 million is also available at the mutual discretion of Celcuity and its lenders.

Adds $170 million in new committed capital, including an additional $50 million for a total of $100 million available upon U.S. Food and Drug Administration (“FDA”) approval of gedatolisib in second-line wild-type advanced breast cancer (“ABC”) patients post-CDK4/6 inhibitor therapy, and $120 million upon achievement of certain commercial revenue milestones. An additional up to $150 million is also available at the mutual discretion of Celcuity and its lenders. Improved Structure and Financial Flexibility: Extends the interest-only period by 14 months, with an additional seven-month extension available upon FDA approval. The maturity date of the facility was also extended by six months.

The amendment significantly enhances Celcuity’s financial flexibility and access to capital following the positive topline data from the PIK3CA wild-type cohort of the pivotal VIKTORIA-1 Phase 3 clinical study. The upsized facility strengthens Celcuity's ability to manage its capital structure efficiently while providing additional funding to support the rolling submission to FDA of its New Drug Application (“NDA”) via FDA’s RTOR program, commercial launch preparations for gedatolisib, and other strategic initiatives.

A Form 8-K outlining the material terms of the amended credit facility will be filed with the Securities and Exchange Commission.
[Source link]: https://www.globenewswire.com/news-release/2025/09/09/3147323/0/en/Celcuity-Announces-Upsized-Senior-Secured-Term-Loan-Facility-of-500-Million-with-Innovatus-Capital-Partners-and-Oxford-Finance.html


[TITLE]NHL CBA establishes a $4M annual fund for retired players’ health care and wellness:
[TEXT]
LAS VEGAS (AP) — Beyond the noticeable changes in the new NHL collective bargaining agreement like expanding the regular season to 84 games and implementing a playoff salary cap is an investment in caring for former players that has not existed until now.

The league and union will contribute $4 million annually to the newly established Retired Players Emergency Healthcare and Wellness Fund. NHL Alumni Association president and executive director Glenn Healy, a retired goaltender, said the plan provides access to a family doctor and a mental wellness professional for any player, “whether you played one shift or 10,000 games.”

Healy, Deputy Commissioner Bill Daly and NHLPA assistant executive director Ron Hainsey shared details
[Source link]: https://apnews.com/article/nhl-retired-players-health-care-45b6a29f55375aa1fe150414eb946727

================================================================================

[Failed to load article at https://www.euractiv.com/section/health-consumers/news/rfk-unveils-plan-to-tackle-childhood-chronic-disease-points-to-europe/]


[Failed to load article at https://financialpost.com/globe-newswire/kfshrc-concludes-strategic-role-at-c3-davos-of-healthcare-new-york-summit]


[TITLE]Leptomeningeal Metastases Market to Exhibit Growth at a Paltry CAGR of 1.9% During the Forecast Period (2025–2034) | DelveInsight:
[TEXT]
New York, USA, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Leptomeningeal Metastases Market to Exhibit Growth at a Paltry CAGR of 1.9% During the Forecast Period (2025–2034) | DelveInsight

The leptomeningeal metastases market is projected to grow steadily due to rising cancer incidence and the increasing prevalence of central nervous system complications in advanced malignancies. Additionally, the expected launch of therapies such as Rhenium-186 obisbemeda (REYOBIQ), Paxalisib, HSV G2072, AZD1390, and others will further propel the leptomeningeal metastases market growth.

DelveInsight’s Leptomeningeal Metastases Market Insights report includes a comprehensive understanding of current treatment practices, emerging leptomeningeal metastases drugs, market share of individual therapies, and current and forecasted leptomeningeal metastases market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).

Leptomeningeal Metastases Market Summary

The total leptomeningeal metastases treatment market size was USD 1.7 billion in 2024, and it is expected to grow positively by 2034 in the leading markets (the US, EU4, UK, and Japan).

The United States accounts for the largest market size of leptomeningeal metastases, i.e, 60% , in comparison to EU4 (Germany, Italy, France, and Spain), the UK, and Japan.

, in comparison to EU4 (Germany, Italy, France, and Spain), the UK, and Japan. In 2024, the total incident cases of leptomeningeal metastases were ~300K in the leading markets (the US, EU4, UK, and Japan).

in the leading markets (the US, EU4, UK, and Japan). Key leptomeningeal metastases companies, including Plus Therapeutics, Kazia Therapeutics, Genentech, Treovir, AstraZeneca, Angiochem, and others, are actively working on innovative leptomeningeal metastases drugs.

and others, are actively working on innovative leptomeningeal metastases drugs. Some of the key leptomeningeal metastases therapies in clinical trials include Rhenium-186 obisbemeda (REYOBIQ), Paxalisib, HSV G2072, AZD1390, ANG1005, and others. These novel leptomeningeal metastases therapies are anticipated to enter the leptomeningeal metastases market in the forecast period and are expected to change the market.

Discover which leptomeningeal metastases medications are expected to grab the market share @ Leptomeningeal Metastases Market Report

Key Factors Driving the Growth of the Leptomeningeal Metastases Market

Rising Incidence of Central Nervous System Metastases

Advancements in systemic cancer therapies have improved overall survival rates, leading to a higher prevalence of CNS metastases, including leptomeningeal metastases. As patients live longer, the occurrence of leptomeningeal metastases as a complication has increased, thereby expanding the patient population requiring specialized treatment. In 2024, the total incident cases of leptomeningeal metastases were approximately 120K in the US, reflecting its significant disease burden and the pressing need for improved diagnostic tools and more effective treatments.

Significant Unmet Clinical Needs

Currently, there are no FDA-approved therapies specifically for leptomeningeal metastases, and the condition is often diagnosed late due to the lack of effective screening methods. This gap presents a substantial opportunity for the development of targeted treatments that can address the unique challenges of leptomeningeal metastases, such as the blood–brain barrier and limited drug penetration into the cerebrospinal fluid.

Emerging Leptomeningeal Metastases Therapies

The development of novel leptomeningeal metastases therapies is gaining momentum. For instance, Plus Therapeutics is advancing Rhenium (186Re) Obisbemeda, a radiotherapeutic targeting leptomeningeal metastases, currently undergoing clinical trials. Additionally, antibody-drug conjugates like Patritumab deruxtecan (Daiichi Sankyo) have shown promising activity in treating leptomeningeal metastases, offering hope for patients with limited options.

Leptomeningeal Metastases Market Analysis

Despite the substantial disease burden, there are currently no therapies approved explicitly for leptomeningeal metastases. Treatment remains largely palliative and multimodal, aimed at symptom relief using off-label agents such as methotrexate, cytarabine, temozolomide, capecitabine, topotecan, and lapatinib, often in combination with radiation therapy. These strategies focus on slowing disease progression and preserving neurological function.

In 2024, the US accounted for nearly 60% of the leptomeningeal metastases market, driven by widespread use of systemic, targeted, intrathecal, and radiation-based interventions. This dominance is supported by favorable reimbursement policies, rapid uptake of novel treatments, and a healthcare system that facilitates high-cost, aggressive therapy approaches.

Pharmaceutical involvement in leptomeningeal metastases has mostly been supportive, with companies contributing investigational drugs or partial funding to academic-led trials rather than leading full-scale development programs. Notable exceptions include Plus Therapeutics, which is actively developing REYOBIQ, a targeted radiotherapeutic for leptomeningeal metastases, and Angiochem, which had advanced ANG1005, a peptide-drug conjugate capable of crossing the blood–brain and blood–CSF barriers. However, its development is currently on hold.

The emerging leptomeningeal metastases treatment landscape has encountered significant challenges. For example, Y-mAbs Therapeutics’ Omburtamab, a radiolabeled monoclonal antibody targeting B7-H3 in CNS tumors and leptomeningeal metastases, completed pivotal trials but received a Complete Response Letter (CRL) from the FDA in 2022, citing insufficient clinical benefit and concerns regarding study design.

Learn more
[Source link]: https://www.globenewswire.com/news-release/2025/09/09/3147250/0/en/Leptomeningeal-Metastases-Market-to-Exhibit-Growth-at-a-Paltry-CAGR-of-1-9-During-the-Forecast-Period-2025-2034-DelveInsight.html


[TITLE]NHL CBA establishes a $4M annual fund for retired players’ health care and wellness:
[TEXT]
LAS VEGAS (AP) — Beyond the noticeable changes in the new NHL collective bargaining agreement like expanding the regular season to 84 games and implementing a playoff salary cap is an investment in caring for former players that has not existed until now.

The league and union will contribute $4 million annually to the newly established Retired Players Emergency Healthcare and Wellness Fund. NHL Alumni Association president and executive director Glenn Healy, a retired goaltender, said the plan provides access to a family doctor and a mental wellness professional for any player, “whether you played one shift or 10,000 games.”

Healy, Deputy Commissioner Bill Daly and NHLPA assistant executive director Ron Hainsey shared details
[Source link]: https://apnews.com/article/nhl-retired-players-health-care-45b6a29f55375aa1fe150414eb946727

================================================================================

[TITLE]Exosome Cell and Gene Therapy Market 2026 Drives by Rising Demand for Personalized Medicine, says Healthcare Experts:
[TEXT]
Ottawa, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The exosome cell and gene therapy
[Source link]: https://www.globenewswire.com/news-release/2025/09/09/3147100/0/en/Exosome-Cell-and-Gene-Therapy-Market-2026-Drives-by-Rising-Demand-for-Personalized-Medicine-says-Healthcare-Experts.html


[TITLE]Prostate Cancer Therapeutics Market Report 2025: Industry to Grow by Nearly $8 Billion by 2030 as the Population Ages and Awareness Grows:
[TEXT]
Dublin, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The "Prostate Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2031F" has been added to ResearchAndMarkets.com's offering.

The Prostate Cancer Therapeutics Market was valued at USD 13.45 billion in 2024 and is expected to reach USD 21.23 billion by 2030, rising at a CAGR of 8.05%. The prostate cancer therapeutics market is experiencing significant growth, driven by rising awareness, increasing incidence rates, and advancements in diagnostic and treatment technologies. As prostate cancer remains one of the most commonly diagnosed cancers in men, there is a growing demand for effective treatment options across all stages of the disease.

The market encompasses a wide range of therapies, including hormone therapy, chemotherapy, immunotherapy, and targeted therapy. Among these, androgen deprivation therapy continues to play a central role, while newer targeted treatments and immunotherapies are gaining traction due to their ability to provide more personalized and effective care.

For instance, according to data from the American Cancer Society, prostate cancer is most prevalent in older men, with around 60% of diagnoses occurring in those aged 65 and above, while it is rare in men under 40. The typical age for a man's first diagnosis is around 67. This significant impact on an aging population drives the demand for prostate cancer therapeutics.

Key Market Drivers

Rising Prevalence of Prostate Cancer: The rising prevalence of prostate cancer is a significant driver propelling the growth of the prostate cancer therapeutics market. For instance, according to the Global Cancer Observatory's GLOBOCAN 2022 report, prostate cancer ranked 4th among all cancer types, with approximately 1.47 million new cases reported in 2022. This high incidence rate significantly increases the demand for effective treatment options, driving the growth of the prostate cancer therapeutics market. Also, November is globally recognized as Prostate Cancer Awareness Month, focusing on raising awareness for prostate cancer in men.

In November 2024, Europa Uomo members in Hungary and Italy contributed to this cause by launching prostate cancer testing programs as part of the 'Movember' campaign. Prostate cancer has become one of the most commonly diagnosed cancers among men worldwide, with its incidence steadily increasing, particularly in aging populations. As life expectancy rises globally, the number of men at risk for prostate cancer also grows, leading to higher diagnosis rates. This trend is especially pronounced in developed countries where healthcare systems are more likely to perform regular screenings, including prostate-specific antigen (PSA) testing, resulting in earlier and more frequent detection of the disease.

The lifestyle changes such as sedentary habits, poor diet, and obesity - factors known to increase the risk of prostate cancer - are becoming more prevalent across both developed and developing nations. As awareness
[Source link]: https://www.globenewswire.com/news-release/2025/09/09/3147042/28124/en/Prostate-Cancer-Therapeutics-Market-Report-2025-Industry-to-Grow-by-Nearly-8-Billion-by-2030-as-the-Population-Ages-and-Awareness-Grows.html


[TITLE]Hepatitis D Market Research Report 2023-2035 | Gilead, GSK, and Janssen Drive Innovation as Biotechs Advance Antivirals, RNA, and Gene Therapies:
[TEXT]
Dublin, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The "Hepatitis D Market - A Global and Regional Analysis: Focus on Treatment Type, Diagnostic Method, and Region - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering.

The global hepatitis D market is experiencing steady growth, driven by several key factors. Firstly, the increasing diagnosis rates of hepatitis D, particularly in regions with a high prevalence of hepatitis B virus (HBV) infections, have led to a greater demand for effective treatment solutions. Secondly, advancements in diagnostic technologies, including improved genetic testing, serological assays, and nucleic acid testing, have enabled earlier and more accurate detection of hepatitis D, leading to better patient outcomes and enhanced disease management. Thirdly, the approval and introduction of novel therapies, such as bulevirtide and antiviral agents targeting HDV replication, have expanded treatment options, offering more targeted and effective solutions for managing chronic hepatitis D.

Additionally, rising awareness among healthcare professionals and patients
[Source link]: https://www.globenewswire.com/news-release/2025/09/09/3146715/28124/en/Hepatitis-D-Market-Research-Report-2023-2035-Gilead-GSK-and-Janssen-Drive-Innovation-as-Biotechs-Advance-Antivirals-RNA-and-Gene-Therapies.html


[TITLE]Life Science Market Size to Soar USD 269.56 Bn Rising at 11.8% CAGR by 2034:
[TEXT]
Ottawa, Sept. 09, 2025 (GLOBE NEWSWIRE) -- According to a study published by Towards Healthcare, a sister company of Precedence Research, the global life science
[Source link]: https://www.globenewswire.com/news-release/2025/09/09/3147025/0/en/Life-Science-Market-Size-to-Soar-USD-269-56-Bn-Rising-at-11-8-CAGR-by-2034.html

================================================================================

No articles found for this sector...

================================================================================

[Failed to load article at https://www.euractiv.com/section/health-consumers/news/rfk-unveils-plan-to-tackle-childhood-chronic-disease-points-to-europe/]


[TITLE]NHL CBA establishes a $4M annual fund for retired players’ health care and wellness:
[TEXT]
LAS VEGAS (AP) — Beyond the noticeable changes in the new NHL collective bargaining agreement like expanding the regular season to 84 games and implementing a playoff salary cap is an investment in caring for former players that has not existed until now.

The league and union will contribute $4 million annually to the newly established Retired Players Emergency Healthcare and Wellness Fund. NHL Alumni Association president and executive director Glenn Healy, a retired goaltender, said the plan provides access to a family doctor and a mental wellness professional for any player, “whether you played one shift or 10,000 games.”

Healy, Deputy Commissioner Bill Daly and NHLPA assistant executive director Ron Hainsey shared details
[Source link]: https://apnews.com/article/nhl-retired-players-health-care-45b6a29f55375aa1fe150414eb946727


[TITLE]NHL CBA establishes a $4M annual fund for retired players' health care and wellness:
[TEXT]
FILE - Glenn Healy responds to questions from the media after a meeting at NHL headquarters, Dec. 4, 2008, in New York. (AP Photo/Frank Franklin II)

FILE - From left to right, Ron Hainsey, NHLPA Assistant Executive Director, Marty Walsh, NHLPA Executive Director, Gary Bettman, NHL Commissioner, and Bill Daly, NHL Deputy Commissioner, pose for photos after a joint press conference before the NHL hockey draft, June 27, 2025, in Los Angeles. (AP Photo/Damian Dovarganes, file)

FILE - From left to right, Ron Hainsey, NHLPA Assistant Executive Director, Marty Walsh, NHLPA Executive Director, Gary Bettman, NHL Commissioner, and Bill Daly, NHL Deputy Commissioner, pose for photos after a joint press conference before the NHL hockey draft, June 27, 2025, in Los Angeles. (AP Photo/Damian Dovarganes, file)

FILE - Glenn Healy responds to questions from the media after a meeting at NHL headquarters, Dec. 4, 2008, in New York. (AP Photo/Frank Franklin II)

FILE - From left to right, Ron Hainsey, NHLPA Assistant Executive Director, Marty Walsh, NHLPA Executive Director, Gary Bettman, NHL Commissioner, and Bill Daly, NHL Deputy Commissioner, pose for photos after a joint press conference before the NHL hockey draft, June 27, 2025, in Los Angeles. (AP Photo/Damian Dovarganes, file)

LAS VEGAS (AP) — Beyond the noticeable changes in the new NHL collective bargaining agreement like expanding the regular season to 84 games and implementing a playoff salary cap is an investment in caring for former players that has not existed until now.

The league and union will contribute $4 million annually to the newly established Retired Players Emergency Healthcare and Wellness Fund. NHL Alumni Association president and executive director Glenn Healy, a retired goaltender, said the plan provides access to a family doctor and a mental wellness professional for any player, “whether you played one shift or 10,000 games.”

Advertisement

Advertisement Advertisement

Healy, Deputy Commissioner Bill Daly and NHLPA assistant executive director Ron Hainsey shared details
[Source link]: https://sports.yahoo.com/article/nhl-cba-establishes-4m-annual-193035716.html


[Failed to load article at https://financialpost.com/globe-newswire/kfshrc-concludes-strategic-role-at-c3-davos-of-healthcare-new-york-summit]

================================================================================

